The senolytic agent ABT263 ameliorates osteoporosis caused by active vitamin D insufficiency through selective clearance of senescent skeletal cells.

Cuicui Yang, Wanxin Qiao, Qi Xue, David Goltzman, Dengshun Miao, Zhan Dong

The Research Center for Bone and Stem Cells, Department of Anatomy, Histology and Embryology, Nanjing Medical University, Nanjing, China.The Research Center for Bone and Stem Cells, Department of Anatomy, Histology and Embryology, Nanjing Medical University, Nanjing, China. · pubmed

Paper

Abstract

Active vitamin D insufficiency accelerates the development of osteoporosis, with senescent bone cells and the senescence-associated secretory phenotype (SASP) playing crucial roles. This study aimed to investigate whether the senolytic agent ABT263 could correct osteoporosis caused by active vitamin D insufficiency by selectively clearing senescent cells.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper addresses the role of senescent cells in osteoporosis, a condition associated with aging, and investigates a senolytic agent as a potential treatment. This aligns with longevity research by targeting the underlying mechanisms of aging, specifically cellular senescence. However, while the findings may contribute to the understanding of osteoporosis and senolytics, the impact is limited as it primarily focuses on a specific condition rather than broader implications for aging or lifespan extension.

Author of this paper? Send a correction.